PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Candidiasis, Vulvovaginal”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1978

Seven-day clotrimazole therapy for vulvovaginal candidiasis.

There were 150 patients with mycologically proven vulvovaginal candidiasis in a randomized, non-cross-over study which compared seven-and 14-day treatment courses of clotrimazole vaginal tablets (Gyne-Lotrimin) with a 14-day treatment course of miconazole nitrate 2% vaginal cream (Monistat). Adequate data for analyses were obtained for 117 patients. When patients were reexamined four or more weeks after completion of therapy, success rates, based on clinical and mycologic criteria, were: 88% for patients treated with clotrimazole for seven days, 84% for clotrimazole 14-day treatment, and 78% for miconazole nitrate 14-day treatment. There were no drug-related adverse reactions. Thus a seven-day course of therapy with clotrimazole is effective as is a 14-day course of either clotrimazole or miconazole nitrate 2% for the treatment of Candida vaginitis. Statistical analysis revealed no significant differences among the clotrimazole seven-and 14-day treatment groups and the miconazole nitrate 14-day treatment group. The shorter period of administration required for this new antifungal agent should result in better patient compliance and an improved success rate in the rate in the treatment of this frequently encountered infection.

Adolescent↗
PubMed1977

Treatment of vulvovaginal candidiasis in pregnancy. A comparative study.

A carefully controlled comparative study showed miconazole nitrate 2% vaginal cream (Monistat) to be a highly effective agent in the treatment of vaginal candidiasis in pregnant subjects. Miconazole nitrate was significantly more effective than nystatin (Mycostatin) in the treatment of vaginal candidiasis in all three trimesters of pregnancy, and also more effective regardless of whether the candidal infection was primary or recurrent. Observations relating to the safety of this therapy during pregnancy were made and discussed.

Acute Disease↗
PubMed1975

Monistat cream (miconazole nitrate) a new agent for the treatment of vulvovaginal candidiasis.

Monistat Cream (miconazole nitrate 2%), a new fungicidal agent indicated for the treatment of vulvovaginal candidiasis, was evaluated in a comparative study with nystatin vaginal tablets (100,-000 units each). A total of 95 pregnant and non-pregnant patients were treated. Miconazole nitrate was administered once daily, at bedtime, for 14 days to 55 pregnant and non-pregnant patients. Overall, 74.5% (41 of 55 patients) were cured with one course of therapy. In contrast, of 40 nystatin-treated patients (both pregnant and non-pregnant) treated twice daily for 15 days, 22 patients (57.8%) were cured with one course of therapy. This difference in cure rates was statistically significant. Side effects were minimal and comparable in the two treatment groups. No recorded instances of birth defects were observed in infants born to mothers in either treatment group. Monistate Cream, in this study, was found to be a safe and effective drug in treating both pregnant and nonpregnant patients with confirmed candidiasis.

Adolescent↗
PubMed1977

Evaluation of Monistat cream (miconazole nitrate 2%) in a reduced regimen for the treatment of vulvovaginal candidiasis.

A carefully conducted study with reduced regimens of Monistat cream (miconazole nitrate 2%) was undertaken to compare the therapeutic cure rates in patients with vulvovaginal candidiasis on Monistat cream for 7, 10 and 14 days. Five clinical investigators participated in the study and randomly assigned 139 patients, who met criteria outlined in the protocol, to either the 7-, 10, or 14-day regimen. Case records of 108 patients were used in evaluating the results. Thirty-one records were classified as invalid and were eliminated from the final analysis. Analysis of the data revealed no statistically significant difference in cure rates between the three regimens. It can be concluded, therefore, that Monistat cream used in a regimen consisting of 7 or 10 days of therapy has a cure rate equivalent to the currently recommended 14-day regimen.

Candidiasis, Vulvovaginal↗
PubMed1979

Short-term topical treatment of vulvovaginal candidiasis with the combination of 5-fluorocytosine and candicidin.

A combination of 5-fluorocytosine (1000 mg) and candicidin (5 mg) was compared with clotrimazole (100 mg) in the treatment of 112 non-pregnant volunteers with vulvovaginal candidiasis. Seventy-two (75%) of the 96 patients treated with 1 or 2 vaginal tablets of the combination product and 10 (62%) of the 16 women treated with clotrimazole for 6 days were cured. The efficacy of the treatments was assessed mycologically and clinically 1 week and 1 month after the therapy. Both treatments were well tolerated and no side-effects could be detected. It is concluded that a short-term vaginal treatment with a 5-fluorocytosine and candicidin combination is effective in vaginal moniliasis, and the brevity of the treatment is an advantage compared with others now available.

Administration, Topical↗
PubMed1978

Vulvovaginal candidiasis treated with clotrimazole cream in seven days compared with fourteen-day treatment with miconazole cream.

Clotrimazole 1 per cent vaginal cream administered daily over a seven-day period was compared with miconazole nitrate 2 per cent vaginal cream administered daily over a 14 day period for the treatment of vulvovaginal candidiasis in a double-blind study of 65 women with clinical symptoms of this condition,, for whom treatment was randomly allocated. When efficacy of treatment was evaluated in 44 of these patients, a success rate, based on both clinical and mycologic criteria, of 75 per cent was found in the 20 patients treated with clotrimazole for seven days as compared with a 63 per cent success rate in the 24 patients treated with miconazole for 14 days. Of the 65 women enrolled in the study, two of the miconazole-treated patients experienced burning sensations, whereas the clotrimazole-treated patients experienced no adverse reactions. Thus, in this group of patients clotrimazole 1 per cent vaginal cream was shown to have a slightly, but not significantly, better efficacy than the miconazole nitrate 2 per cent vaginal cream, with no adverse reactions and in half the treatment time.

Adolescent↗
PubMed1978

Vulvovaginal candidiasis in pregnancy treated with clotrimazole.

An open trial of local clotrimazole therapy in 56 pregnant women with vulvovaginal candidiasis is reported. The diagnosis was confirmed by mycotic culture. The patients were given one vaginal tablet daily and cream was applied to the vulva 2 or 3 times daily. Their male partners were treated with cream only. The duration of therapy was 6 days. Fifty of the patients (89.3%) were clinically cured after 6 days of therapy. Six patients (10.7%) had slight complaints and 10 (17.9%) without symptoms or signs of infection harboured Candida albicans or other yeast species in the genital tract. Six of the patients were given a second treatment with clotrimazole and their remaining symptoms subsided. Candidiasis recurred later in pregnancy in 4 of the 56 patients studied. The implications of the presence of Candida in the genital tract are discussed. It is concluded that clotrimazole is an effective antimycotic agent which can be used for vulvovaginal candidasis during pregnancy without causing side effects. Two of the patients had trichomoniasis concurrently. One of these was cured with clotrimazole.

Administration, Topical↗
PubMed1979

[Vulvovaginal candidiasis in pregnancy and its treatment with clotrimazole].

The Writers have carried out a study on 624 pregnant women pointing out that the incidence of vulvovaginal candidiasis is notably increased (35,5%) during pregnancy with a slight difference in the three three-monthly periods of pregnancy. Controls on 195 women after treatment with clotrimazole showed an average percentage of recovery of 83% with a maximum of 87% in the second three-monthly period.

Adolescent↗
PubMed1979

A dose-response study with Monistat cream.

A randomized multiregimen clinical study was undertaken using Monistat Cream for the treatment of vulvovaginal candidiasis. The objective of the study was to find if there is a shorter regimen comparable in effectiveness to the currently marketed 14-day regimen. The results indicate that there is no significant difference between the cure rate obtained for 7 days of therapy and for 14 days of therapy.

Candidiasis, Vulvovaginal↗
PubMed1977

[Vulvovaginal mycoses-stort-term treatment with Econazole (author's transl)].

The short-term treatment (3 days) of mycologically demonstrated vulvovaginal candidiasis with econazole vaginal suppositories 150 mg was tested in a population of 194 women. Substancial prerequisites for thorough and complete performance of the therapy are high cure rates (93,3%), prompt therapeutic results, minor burden for the patient and good tolerability. In view of the vital danger for the newborn provoked by candidiasis morbidity, this short-term therapy is also indicated for prenatal prophylaxis.

Adolescent↗
PubMed2025

Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM.

Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients who are immunocompromised or critically ill. In contrast, mucocutaneous forms of candidiasis, such as oral thrush and vulvovaginal candidiasis, can occur in otherwise healthy individuals. Although mucocutaneous candidiasis is generally not life-threatening, it can cause considerable discomfort, recurrent infections, and complications, particularly in patients with underlying conditions such as diabetes or in those taking immunosuppressive therapies. The rise of difficult-to-treat Candida infections is driven by new host factors and antifungal resistance. Pathogens, such as Candida auris (Candidozyma auris) and fluconazole-resistant Candida parapsilosis, pose serious global health risks. Recent taxonomic revisions have reclassified several Candida spp, potentially causing confusion in clinical practice. Current management guidelines are limited in scope, with poor coverage of emerging pathogens and new treatment options. In this Review, we provide updated recommendations for managing Candida infections, with detailed evidence summaries available in the appendix.

Humans↗